Drug General Information
Drug ID	D03RMN
Former ID	DIB009612
Drug Name	1069C
Drug Type	Small molecular drug
Indication	Cancer [ICD9: 140-229; ICD10:C00-C96]		Phase 1	[534331]
Structure		Download 2D MOL 3D MOL
Formula	C18H20N4O6
Canonical SMILES	COC1=CC(=CC(=C1OC)OC)COC2=NN3C=C(N=C3C=C2)NC(=O)OC
InChIKey	UMSHZWFCVXIDEO-UHFFFAOYSA-N
PubChem Compound ID	6918099
PubChem Substance ID	12014341, 14805061, 17194677, 43529494, 57371797, 75728825, 103190297, 104121844, 114787435, 129390496, 224981209, 234420077
Target and Pathway
Target(s)	Tubulin beta	Target Info	Modulator	[550941], [551871]
KEGG Pathway	Phagosome
	Gap junction
	Pathogenic Escherichia coli infection
NetPath Pathway	FSH Signaling Pathway
	TCR Signaling Pathway
	EGFR1 Signaling Pathway
PANTHER Pathway	Cytoskeletal regulation by Rho GTPase
	Huntington disease
Reactome	Regulation of PLK1 Activity at G2/M Transition
	Loss of Nlp from mitotic centrosomes
	Recruitment of mitotic centrosome proteins and complexes
	Loss of proteins required for interphase microtubule organization?from the centrosome
	Anchoring of the basal body to the plasma membrane
WikiPathways	Parkin-Ubiquitin Proteasomal System pathway
	Pathogenic Escherichia coli infection
	Mitotic G2-G2/M phases
References
Ref 534331	Phase I trial and pharmacokinetics of the tubulin inhibitor 1069C85--a synthetic agent binding at the colchicine site designed to overcome multidrug resistance. Br J Cancer. 1997;75(4):608-13.
Ref 550941	Patent WO2005108424 A1.
Ref 551871	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.